Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.76 |
| ▸ | RAF1 | P04049 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.76 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488017 | 1.00 | EGFR (0.76) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL5816218 | 0.91 | MAPK9 (0.65) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL5818972 | 0.90 | EGFR (0.64) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL6218705 | 0.89 | KCNH2 (0.65) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL5818632 | 0.89 | KCNH2 (0.65) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL6218709 | 0.89 | KCNH2 (0.65) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL5814019 | 0.88 | EGFR (0.59) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL5819620 | 0.87 | MAPK9 (0.59) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL6214573 | 0.86 | EGFR (1.00) | EGFRRAF1ERBB2SRCKDR | |
| SCHEMBL375202 | 0.86 | EGFR (1.00) | EGFRRAF1ERBB2SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | disclosed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | EGFR 1067/4885RAF1 115/4885ERBB2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.